Skip to main content

A phase Ib dose-escalation study of TRC105 (anti-endoglin antibody) in combination with pazopanib in patients with advanced soft tissue sarcoma (STS)

Publication ,  Conference
Attia, S; Riedel, RF; Robinson, SI; Conry, RM; Sankhala, KK; Seon, BK; Alvarez, D; Adams, BJ; Theuer, CP; Maki, RG
Published in: JOURNAL OF CLINICAL ONCOLOGY
May 20, 2015

Duke Scholars

Published In

JOURNAL OF CLINICAL ONCOLOGY

EISSN

1527-7755

ISSN

0732-183X

Publication Date

May 20, 2015

Volume

33

Issue

15

Location

Chicago, IL

Publisher

AMER SOC CLINICAL ONCOLOGY

Conference Name

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Attia, S., Riedel, R. F., Robinson, S. I., Conry, R. M., Sankhala, K. K., Seon, B. K., … Maki, R. G. (2015). A phase Ib dose-escalation study of TRC105 (anti-endoglin antibody) in combination with pazopanib in patients with advanced soft tissue sarcoma (STS). In JOURNAL OF CLINICAL ONCOLOGY (Vol. 33). Chicago, IL: AMER SOC CLINICAL ONCOLOGY.
Attia, Steven, Richard F. Riedel, Steven Ian Robinson, Robert Martin Conry, Kamalesh Kumar Sankhala, Ben K. Seon, Delia Alvarez, Bonne J. Adams, Charles P. Theuer, and Robert G. Maki. “A phase Ib dose-escalation study of TRC105 (anti-endoglin antibody) in combination with pazopanib in patients with advanced soft tissue sarcoma (STS).” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 33. AMER SOC CLINICAL ONCOLOGY, 2015.
Attia S, Riedel RF, Robinson SI, Conry RM, Sankhala KK, Seon BK, et al. A phase Ib dose-escalation study of TRC105 (anti-endoglin antibody) in combination with pazopanib in patients with advanced soft tissue sarcoma (STS). In: JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY; 2015.
Attia, Steven, et al. “A phase Ib dose-escalation study of TRC105 (anti-endoglin antibody) in combination with pazopanib in patients with advanced soft tissue sarcoma (STS).” JOURNAL OF CLINICAL ONCOLOGY, vol. 33, no. 15, AMER SOC CLINICAL ONCOLOGY, 2015.
Attia S, Riedel RF, Robinson SI, Conry RM, Sankhala KK, Seon BK, Alvarez D, Adams BJ, Theuer CP, Maki RG. A phase Ib dose-escalation study of TRC105 (anti-endoglin antibody) in combination with pazopanib in patients with advanced soft tissue sarcoma (STS). JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY; 2015.

Published In

JOURNAL OF CLINICAL ONCOLOGY

EISSN

1527-7755

ISSN

0732-183X

Publication Date

May 20, 2015

Volume

33

Issue

15

Location

Chicago, IL

Publisher

AMER SOC CLINICAL ONCOLOGY

Conference Name

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences